leadf
logo-loader
viewLexaGene Holdings Inc.
(
TSX-V:LXGOTCQB:LXXGF
)

Could LexaGene Holdings' pathogen detection platform be a difference-maker in the fight against COVID-19?

The firm is pioneering the first open-access fully-automated pathogen detection platform for use in diagnostics and sample analysis

LexaGene Holdings Inc. -
LexaGene is pursuing an FDA emergency use authorization for Covid testing, which would open a whole new window of opportunity

LexaGene Holdings Inc (CVE:LXG, OTCMKTS:LXXGF) is at the leading edge of med-tech in pioneering the first open-access fully-automated pathogen detection platform for use in diagnostics and sample analysis.

While its MiQLab doesn’t have regulatory sign-off for human clinical diagnostics, LexaGene is pursuing an FDA emergency use authorization for Covid testing, which would open a whole new window of opportunity.

In the meantime, it recently launched an early access program for its MiQLab aimed at the veterinary and open-access markets.

To hear more from CEO and founder Jack Regan, sign up for the Proactive Virtual Forum on Tuesday October 27, from 1pm EST.

CLICK HERE TO REGISTER

About the event:

  • Ours is an audience of astute high net worth investors, fund managers, private client brokers and analysts
  • We look beyond the numbers and meet the people creating the value for shareholders

The format:

  • Each company has a presentation slot followed by Q & A, giving you the chance to discover the real story
  • You can watch the event afterwards on our YouTube channel

CLICK HERE TO REGISTER

Quick facts: LexaGene Holdings Inc.

Follow
TSX-V:LXG

Price: 0.46 CAD

Market Cap: $54.68 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

LexaGene MiQLab on display as the company highlights unique features at WVC...

LexaGene CEO Dr. Jack Regan joined Steve Darling from Proactive on the floor of the 93rd annual WVC conference. This conference in Las Vegas is a gathering of veterinary marketplace leaders. Regan, who is a highlight speaker at the event, shared more with Proactive about his topic “In-Clinic...

1 week, 1 day ago

2 min read